LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Immunitas Therapeutics and Millions of Other Companies

Sign up for full access to Immunitas Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Key Program Advancement Immunitas Therapeutics is advancing IMT-009, a first-in-class T & NK cell modulator targeting CD161, for the treatment of solid tumors and hematological malignancies. This innovative program presents a significant sales opportunity for medical facilities and oncology clinics looking to offer cutting-edge immuno-oncology treatments to their patients.

Strategic Investment With significant funding of $58 million and recent investments from prominent organizations like Agent Capital, Alexandria Venture Investments, and Merck Ventures, Immunitas Therapeutics has the financial backing to expand its operations and partnerships. This financial stability presents a promising sales opportunity for biotech suppliers and service providers looking to collaborate with well-funded research and development teams.

Key Technology Integration Immunitas Therapeutics leverages a tech stack including jQuery CDN, Squarespace, and Webpack to support its research and development activities. Tech companies specializing in biotechnology software solutions, data analytics, and laboratory equipment can explore partnerships with Immunitas to enhance their offerings for the biotech industry.

Strategic Key Personnel Addition The appointment of Annalisa D'Andrea as Chief Scientific Officer and Lynette Herscha as Chief Operating Officer brings top-tier talent to Immunitas Therapeutics, enhancing the company's scientific expertise and operational capabilities. This development creates sales opportunities for recruitment agencies specializing in life sciences to offer their services to support the company's growth.

Market Expansion with Novel Therapies Immunitas Therapeutics is developing a novel anti CLEC2D-TLR9 agonist immune stimulating antibody complex, expanding its portfolio beyond IMT-009. This diversification provides sales potential for pharmaceutical distributors and healthcare providers seeking to offer a range of innovative immunotherapy solutions to meet the evolving needs of cancer treatment.

Similar companies to Immunitas Therapeutics

✕

Access Insights for Immunitas Therapeutics and Millions of Other Companies

Sign up for full access to Immunitas Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Immunitas Therapeutics Tech Stack

Immunitas Therapeutics uses 8 technology products and services including jQuery CDN, Squarespace, Cart Functionality, and more. Explore Immunitas Therapeutics's tech stack below.

  • jQuery CDN
    Content Delivery Network
  • Squarespace
    Content Management System
  • Cart Functionality
    E-commerce
  • Google Font API
    Font Scripts
  • Choices
    Javascript Libraries
  • Webpack
    Miscellaneous
  • Open Graph
    Miscellaneous
  • HSTS
    Security

Media & News

Immunitas Therapeutics's Email Address Formats

Immunitas Therapeutics uses at least 1 format(s):
Immunitas Therapeutics Email FormatsExamplePercentage
FLast@immunitastx.comJDoe@immunitastx.com
50%
FLast@immunitastx.comJDoe@immunitastx.com
50%

Frequently Asked Questions

Where is Immunitas Therapeutics's headquarters located?

Minus sign iconPlus sign iconImmunitas Therapeutics's main headquarters is located at 21 Hickory Dr Waltham, Massachusetts 02451 US. The company has employees across 2 continents, including North AmericaEurope.

What is Immunitas Therapeutics's official website and social media links?

Minus sign iconPlus sign iconImmunitas Therapeutics's official website is immunitastx.com and has social profiles on LinkedIn.

How much revenue does Immunitas Therapeutics generate?

Minus sign iconPlus sign icon As of August 2024, Immunitas Therapeutics's annual revenue reached $1.8M.

What is Immunitas Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconImmunitas Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Immunitas Therapeutics have currently?

Minus sign iconPlus sign iconAs of August 2024, Immunitas Therapeutics has approximately 32 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: A. W.Chief Scientific Officer: P. A.Chief Operating Officer: L. H.. Explore Immunitas Therapeutics's employee directory with LeadIQ.

What industry does Immunitas Therapeutics belong to?

Minus sign iconPlus sign iconImmunitas Therapeutics operates in the Biotechnology Research industry.

What technology does Immunitas Therapeutics use?

Minus sign iconPlus sign iconImmunitas Therapeutics's tech stack includes jQuery CDNSquarespaceCart FunctionalityGoogle Font APIChoicesWebpackOpen GraphHSTS.

What is Immunitas Therapeutics's email format?

Minus sign iconPlus sign iconImmunitas Therapeutics's email format typically follows the pattern of . Find more Immunitas Therapeutics email formats with LeadIQ.

How much funding has Immunitas Therapeutics raised to date?

Minus sign iconPlus sign icon As of August 2024, Immunitas Therapeutics has raised $58M in funding. The last funding round occurred on Aug 18, 2021 for $58M.

When was Immunitas Therapeutics founded?

Minus sign iconPlus sign iconImmunitas Therapeutics was founded in 2019.
Immunitas Therapeutics

Immunitas Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

✕

Access Insights for Immunitas Therapeutics and Millions of Other Companies

Sign up for full access to Immunitas Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
21 Hickory Dr Waltham, Massachusetts 02451 US
Website
immunitastx.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $58M

    Immunitas Therapeutics has raised a total of $58M of funding over 2 rounds. Their latest funding round was raised on Aug 18, 2021 in the amount of $58M.

  • $10M

    Immunitas Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $58M

    Immunitas Therapeutics has raised a total of $58M of funding over 2 rounds. Their latest funding round was raised on Aug 18, 2021 in the amount of $58M.

  • $10M

    Immunitas Therapeutics's revenue is in the range of $10M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Immunitas Therapeutics and Millions of Other Companies

Sign up for full access to Immunitas Therapeutics information.
No credit card needed
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.